,
heart,
and cardiovascular diseases)
Table of contents :
|
|
|
and TIE2
receptor tyrosine kinases have essential roles in vascular development
and maintenance.,
but not of mature endothelial cells, promotes neovascularization after
ischemia. Notably, the protease cathepsin L (CathL) is highly expressed
in EPC as opposed to endothelial cells and was essential for matrix degradation
and invasion by EPC in vitro. CathL-deficient mice show impaired
functional recovery following hind limb ischemia, supporting the concept
of a crucial role for CathL in postnatal neovascularization. Infused CathL-deficient
progenitor cells neither homed to sites of ischemia nor augmented neovascularization.
Forced expression of CathL in mature endothelial cells considerably enhanced
their invasive activity and sufficed to confer their capacity for neovascularization
in
vivoref.,
165,
189
or 206
: bone marrow mononuclear cells are recruited to the sites of VEGF-induced
neovascularization but are not incorporated into the newly formed vesselsref.
Injection into the left lateral cerebral ventricle of the Mongolian gerbil
of an AAV vector capable of expressing the 165-amino-acid isoform of VEGF
(VEGF165) induces EPO expression in the hippocampal pyramidal
layers and in the frontal cortex of the gerbil, particularly after the
18th day following treatment with the vector, which suggests that VEGF165
could act as a hypoxic-like signal for EPO productionref
activates Raf-1 via p21-activated
protein kinase 1 (PAK-1) phosphorylation of serines 338 and 339, resulting
endothelial cell protection from the intrinsic (stress) pathway of apoptosis.
VEGF-A121
activates Raf-1 via c-Src
kinase (CSK), leading to phosphorylation of tyrosines 340 and 341 and
MEK1-dependent protection from extrinsic (receptor)-mediated apoptosis.
WAVE2
/ WASF2 is essential for angiogenesis (actin reorganization in isolated
endothelial cells lacking WAVE2 was defective, as revealed by the decreased
formation of movement-generating lamellipodia and membrane ruffles in response
to vascular endothelial growth factor as compared with wildtype cells).
expressed by bone marrow stromal cells is essential for VEGF-induced mobilization
of endothelial
progenitor cells (EPC).
Regeneration processes are impaired in ischemic heart disease patients,
who are characterized by a reduced systemic NO bioactivity.ref)
(TIMPs)
that spans the first 4 of 5 kringle domains, generated by cleavage
of plasminogen by a macrophage-derived metalloelastase or other MMPs. Angiostatin
can inhibit bFGF-induced endothelial cell proliferation. It has been demonstrated
that other fragments of plasminogen, such as the first 3 kringle (K1-3)
domains and kringle 5 (K5) exhibit potent inhibitory activities on endothelial
cell proliferation. Mutant plasminogen with a furin cleavage consensus
sequence (-ArgXLys/ArgArg) between K3 and K4 has been used.
inhibits the catalytic activities of both MMP-2
and membrane-type 1 MMP (MT1-MMP)
(NC10 domain) inhibits EC proliferation and migration (data on apoptosis
are not available yet), and tumor. Its receptor is unknown
(NC1 domain), one of the components of vascular basement membranes, inhibits
EC proliferation, migration, apoptosis and tumour. Its receptor is a1b1
integrin
(NC1 domain), one of the components of vascular basement membranes, inhibits
EC proliferation, migration, apoptosis and tumour. Its receptor is unknown
(NC1 domain), one of the components of vascular basement membranes, which
binds to avb3
integrin expressed by tumour-associated blood vessels (b3
integrin is primarily expressed by blood vessels that are associated
with large tumours (500 mm3 or greater) and inhibits tumour
and EC proliferation and apoptosis, but not migration; instead blood vessels
that are associated with healing wounds express only the b1
integrin and are tumstatin-insensitive)
(NC1 domain), one of the components of vascular basement membranes, inhibits
EC proliferation (data not available on migration and apoptosis and tumour).
Its receptor is unknown.
to its heterodimeric receptor—VEGFR2
/ Flk1
and neuropilin
1 (NP-1 / Nrp1)—activates the Notch signalling pathway in the endothelium,
causing induction of ephrin B2
expression and suppression of ephrin receptor
B4
expression to establish arterial identity. Little is known about vein identity
except that it involves ephrin receptor B4expression, because Notch
signalling is not activated in veins; an unresolved question is how vein
identity is regulated. COUP-TFII / Nr2f2,
a member of the orphan nuclear receptor superfamily, is specifically expressed
in venous but not arterial endothelium. Ablation of COUP-TFII in endothelial
cells enables veins to acquire arterial characteristics, including the
expression of arterial markers NP-1 and Notch signalling molecules, and
the generation of haematopoietic cell clusters. Furthermore, ectopic expression
of COUP-TFII in endothelial cells results in the fusion of veins and arteries
in transgenic mouse embryos. Thus, COUP-TFII has a critical role in repressing
Notch signalling to maintain vein identity, which suggests that vein identity
is under genetic control and is not derived by a default pathwayref.
+,
VEGFR-2+,
B2+
in TEM.
and multiple myeloma
(when PO2 < 80 mmHg if PCO2 is constant,
< 60 mmHg if PCO2 varies) > hypercapnia,
or acidemia
resulting in an increase in blood pressure, cardiac rate, and respiratory
movements. Another function may be as an endocrine gland. It is innervated
by a plexus of glossopharyngeal, vagal, and sympathetic components.
and aortic arch that is stimulated by changes
in blood volume. They inhibit the vagus nerve and indirectly increase the
orthosympathetic tone => reflex vasocostrition of muscular arteriolae and
veinsref
=| BK
=> B2
=> NOS
=> NO.
)
: that propelled by the fetal heart through the fetus, umbilical
cord, and chorionic villi of the placenta
=>
to the various parts of the body. The wall of an artery consists typically
of
